US FDA Announces Plans To Resume Domestic Inspections
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
You may also be interested in...
GAO report offers new data on the impact of COVID on FDA’s drug inspections. (It was big.)
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
US FDA suggests meeting with investigators onsite by video instead of in person, moving document rooms outside, avoiding paper and more. UK MHRA shares similar recommendations.